Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 6, 1999, Pages 791-799

  Leadley Jr , Robert J ^a   Morgan, Suzanne R ^a   Bentley, Ross ^a   Bostwick, Jeffrey S ^a   Kasiewski, Charles J ^a   Heran, Christopher ^a   Chu, Valeria ^a   Brown, Karen ^a   Moxey, Phillip ^a   Richard Ewing, W ^a   Pauls, Henry ^a   Spada, Alfred P ^a   Perrone, Mark H ^a   Dunwiddie, Christopher T ^a,b  

^a Cardiovascular Drug Discovery   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Anticoagulant; Antithrombotic; Factor Xa; RPR120844

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; N [1 (2 AMINOIMINOMETHYL 4 THIENYLMETHYL) 2 OXO 3 PYRROLIDINYL] 7 METHOXY N METHYL 2 NAPHTHALENESULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; CAROTID ARTERY THROMBOSIS; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT;

ANIMALS; BLOOD COAGULATION TESTS; CAROTID ARTERY THROMBOSIS; DOGS; FACTOR XA; FEMALE; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; HALF-LIFE; HEPARIN; INJECTIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; MACACA MULATTA; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; THIOPHENES;

EID: 0032750094     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199912000-00004     Document Type: Article

References (23)

1. Dunwiddie C, Thornberry NA, Bull HG, et al. Antistasin, a leech-derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989;264: 16694-9.
2. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990;248:593-6.
3. Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci U S A 1995;92:6152-6.
4. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992;85:8805-15.
5. Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrin 1996;7:39-48.
6. Lynch JJ, Sitko GR, Mellott MJ, et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy: a comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994;28:78-85.
7. Lefkovits J, Malycky JL, Rao JS, et al. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J Am Col Cardiol 1996;28:1858-65.
8. Kotze HF, Lamprecht S, Badenhorst PN, Roodt JP, vanWyk V. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects. Thromb Haemost 1997;77:1137-42.
9. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 1996;16:1285-91.
10. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1995.
11. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990;60:269-80.
12. Bostwick JS, Bentley R, Morgan S, et al. RPR120844, a novel, specific inhibitor of coagulation factor Xa, inhibits venous thrombus formation in the rabbit. Thromb Haemost 1999;81:157-60.
13. Taniuchi Y, Sakai Y, Hisamichi N, et al. Biochemical and pharmacological characterization of YM-60828: a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998;79:543-8.
14. Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a: a highly selective factor Xa inhibitor. Thromb Res 1995;80:99-104.
15. Herbert JM, Bernat A, Dol R, Herault JP, Crepon B, Lormeau JC. DX 9065, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996;276:1030-8.
16. Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 1997;339:141-6.
17. Rebello SS, Blank HS, Rote WE, Vlasuk GP, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997;283:91-9.
18. Shaffer LW, Davidson JT, Vlasuk GP, Siegel PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991;84:1741-8.
19. Shaffer LW, Davidson JT, Vlasuk GO, Dunwiddie CT, Siegl PKS. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb 1992; 12:879-85.
20. Schumaker WA, Steinbacher TE, Heran CL, Megill JR, Durham SK. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 1993;69:509-14.
21. Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents: implication in drug development. Thromb Haemost 1995;74:473-81.
22. Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997;78:1366-71.
23. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor Xa in nonhuman primates. Circulation 1995;92:485-91.